With 13 years of experience and an outstanding record of performance, the HIV Prevention Trials Network (HPTN) Laboratory Center (LC) is optimally positioned to support the HPTN in 2013 and beyond. As part of the HPTN Leadership Group, the LC will help shape the network's scientific agenda. The HPTN LC will oversee laboratory activities at study sites;perform Quality Control/Quality Assurance (QA/QC) and specialized testing for HPTN protocols;evaluate and validate assays for use in HPTN protocols;develop novel assays to achieve study objectives;and perform ancillary studies related to HIV prevention. The HPTN LC has comprehensive QA/QC, Virology, and Pharmacology Cores, with Support Laboratories in other key areas (Sexually Transmitted Diseases, Microbiology, Immunology, and Toxicology). The HPTN LC has extensive experience supporting HIV prevention trials in the United States, South America, Asia, and Africa and has led efforts to harmonize laboratory procedures across networks and in other groups. The HPTN LC has supported HPTN protocols evaluating behavioral, biomedical, and structural interventions for HIV prevention, often delivered in combination in a wide range of settings and non-traditional venues. This includes observational, Phase I, Phase II and Phase III studies, with interventions delivered to HIV uninfected individuals, HIV-infected individuals, couples, cohorts, and communities. HPTN study populations include adolescents, women, men who have sex with men, serodiscordant couples, injection drug users, and individuals with acute HIV infection, with some trials enrolling >50,000 participants.
The Specific Aims of the HPTN LC are:
Aim 1 : To provide leadership, expertise, and laboratory support to the HPTN;
Aim 2 : To support site laboratories and ensure the quality of HPTN laboratory results;
Aim 3 : To advance HIV prevention science through assay development and biomedical research. A strong and effective LC is particularly important in the HPTN because of the vast international scope, diversity, and complexity of HIV prevention trials. This award will enable the HPTN to continue its mission to identify effective strategies for HIV prevention that will help end the HIV/AIDS epidemic.

Public Health Relevance

The goal of HIV Prevention Trials Network (HPTN) is to identify effective strategies for HIV prevention. The HPTN Laboratory Center (LC) is part of the HPTN leadership group. HPTN LC investigators will oversee laboratory testing performed at study sites, analyze samples collected in HPTN studies, develop novel laboratory assays, and perform laboratory-related research relevant to HIV prevention.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-TS-A (S1))
Program Officer
Gilbreath, Michael J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Jennings, Larissa; Rompalo, Anne M; Wang, Jing et al. (2015) Prevalence and correlates of knowledge of male partner HIV testing and serostatus among African-American women living in high poverty, high HIV prevalence communities (HPTN 064). AIDS Behav 19:291-301
Grinsztejn, Beatriz; Hosseinipour, Mina C; Ribaudo, Heather J et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 14:281-90
Kuo, Irene; Golin, Carol E; Wang, Jing et al. (2014) Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend 139:93-9
Irvin, R; Wilton, L; Scott, H et al. (2014) A study of perceived racial discrimination in Black men who have sex with men (MSM) and its association with healthcare utilization and HIV testing. AIDS Behav 18:1272-8
Lucas, Gregory M; Young, Alicia; Donnell, Deborah et al. (2014) Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Drug Alcohol Depend 142:139-45
Coates, Thomas J; Kulich, Michal; Celentano, David D et al. (2014) Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health 2:e267-77
Chen, Iris; Cummings, Vanessa; Fogel, Jessica M et al. (2014) Low-level Viremia early in HIV infection. J Acquir Immune Defic Syndr 67:405-8
Cori, Anne; Ayles, Helen; Beyers, Nulda et al. (2014) HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One 9:e84511
Van Der Pol, Barbara; Williams, James A; Taylor, Stephanie N et al. (2014) Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol 52:885-9
Longosz, Andrew F; Morrison, Charles S; Chen, Pai-Lien et al. (2014) Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr 65:390-6

Showing the most recent 10 out of 35 publications